blue cross blue shield glp-1 coverage to stop covering popular weight-loss drugs Issue Brief May 2024: Real-world

Description

Harvard geneticist David Sinclair reveals a rare but serious blindness risk linked to GLP-1 drugs, estimating 20,00030,000 NAION cases per year in

Satiety regulation (reduces appetite, aiding in weight loss)

Stool softeners don't address the root cause

Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver ...

Heart failure (HF) remains one of the cardiovascular diseases (CVDs) associated with a high unmet medical need due to high morbidity and mortality rates and ...